aThe State Key Laboratory of Cardiovascular Disease, Heart Failure Center of Fuwai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing
bThe Affiliated Hospital of Gansu University of Chinese Medicine, Lanzhou, China
Correspondence to Jian Zhang, The State Key Laboratory of Cardiovascular Disease, Heart Failure Center of Fuwai Hospital, 167 Beilishi Road, 100037 Beijing, China. Tel: +86 010 88396180; fax: +86 010 88396180; e-mail: [email protected]
Abbreviations: ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; BP, blood pressure; CCB, calcium channel blocker; CI, confidence interval; HBP, high blood pressure; HF, heart failure; HFmrEF, heart failure with mid-range ejection fraction; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; HR, hazard ratio; LVEF, left ventricular ejection fraction; non-HFrEF, non-heart failure with reduced ejection fraction; NT-proBNP, N terminal pro B type natriuretic peptide; NYHA, New York Heart Association
Received 29 May, 2020
Revised 14 July, 2020
Accepted 29 July, 2020
Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Website (http://www.jhypertension.com).
